Compass Pathways (NASDAQ:CMPS) Trading 8.8% Higher - What's Next?

Key Points

• Shares of Compass Pathways were up 8.8%, trading as high as $7.45 and last at $7.4610 on Tuesday, with about 1.91 million shares changing hands—roughly 38% below the stock's average session volume.
• Several analysts raised price targets (e.g., Canaccord to $20, Morgan Stanley to $18, HC Wainwright to $70), leaving a consensus “Moderate Buy” with an average target price of $22.13; ratings split: 1 Strong Buy, 6 Buy, 1 Hold, 1 Sell.
• Compass is a clinical-stage biotech developing psilocybin therapy (COMP360) for treatment‑resistant depression—its Phase IIb program has received Breakthrough Therapy designation and the company has a market cap of about $713 million.

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report)'s stock price shot up 8.8% on Tuesday . The company traded as high as $7.45 and last traded at $7.4610. 1,912,238 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 3,097,420 shares. The stock had previously closed at $6.86.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Canaccord Genuity Group raised their target price on shares of Compass Pathways from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, February 18th. Morgan Stanley increased their price target on Compass Pathways from $11.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 18th. Compass Point set a $15.00 price objective on Compass Pathways in a report on Thursday, February 12th. HC Wainwright upped their target price on Compass Pathways from $40.00 to $70.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Finally, Royal Bank Of Canada increased their target price on Compass Pathways from $21.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Compass Pathways currently has an average rating of "Moderate Buy" and an average target price of $22.13.

Compass Pathways Stock Performance

The company has a market cap of $712.95 million, a PE ratio of -2.73 and a beta of 1.90. The stock's 50 day simple moving average is $6.98 and its two-hundred day simple moving average is $6.19. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Toronto Dominion Bank grew its position in Compass Pathways by 152.9% during the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company's stock valued at $17,447,000 after acquiring an additional 1,529,013 shares during the period. Jefferies Financial Group Inc. purchased a new position in shares of Compass Pathways in the 3rd quarter worth about $7,890,000. Nantahala Capital Management LLC lifted its stake in shares of Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company's stock valued at $11,704,000 after purchasing an additional 1,350,698 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Compass Pathways in the 3rd quarter valued at about $6,926,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Compass Pathways during the 2nd quarter worth about $3,011,000. Institutional investors and hedge funds own 46.19% of the company's stock.

Compass Pathways Company Profile

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.